Kodiak Sciences Inc.

NasdaqGM:KOD 株式レポート

時価総額：US$2.6b

Kodiak Sciences マネジメント

マネジメント 基準チェック /34

Kodiak Sciencesの CEO はVictor Perlrothで、 Jun2009年に任命され、 の在任期間は 16.92年です。 の年間総報酬は$ 2.50Mで、 31.7%給与と68.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の4.71%を直接所有しており、その価値は$ 120.64M 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と7.9年です。

主要情報

Victor Perlroth

最高経営責任者

US$2.5m

報酬総額

CEO給与比率31.71%
CEO在任期間16.9yrs
CEOの所有権4.7%
経営陣の平均在職期間4.8yrs
取締役会の平均在任期間7.9yrs

経営陣の近況

Recent updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha
分析記事 • Oct 03

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...
Seeking Alpha • Feb 24

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies. From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels. Read the full article on Seeking Alpha
分析記事 • Dec 13

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 15

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Summary Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies due to unexpected cataract development. Tarcocimab showed superiority over sham and better tolerability in a Phase 3 diabetic retinopathy trial, prompting Kodiak to resurrect the asset and initiate more pivotal trials. My previous recommendation was "sell" due to high risk and limited upside, but recent positive data and clinical advancements warrant a reassessment. KOD merits a "hold" ahead of key developments in their clinical trials, but this isn't for the faint of heart and works best within a barbell portfolio. Read the full article on Seeking Alpha
分析記事 • Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Dec 29

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Sep 09

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • May 26

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Jan 04

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Sep 25

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Shares have perked up since announcing the BEACON top line data. We are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve. The following segment was excerpted from this fund letter. Kodiak Sciences (KOD) A great example of companies that can perform in any environment is busted biotech world. One of the sectors undergoing the most pain in the recent year has been biotech, where we have invested in since 2004. Subsequent to the quarter end, we added a second company to our portfolio, and are actively engaged in researching more busted biotechs. Both our newest, Kodiak Sciences (KOD) and MEI Pharma (MEIP) have important regulatory catalysts in the very near future, and they have ample cash to get them through to the value inflection catalyst points. These are the types of names that can perform in any economic environment. The downside is protected by the cash position, and yes, while those cash positions are being spent on funding drug development, the long runways give us ample time to realize these value inflection milestones. We have been buyers of both companies as the market remains relatively indifferent to the looming regulatory updates. Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab (formerly KSI-301), failed its very poorly designed clinical trial. The company’s drug will fill a significant unmet medical need, particular for diabetic and elderly patients with macular edema who have given up going to their doctor every 1-2 months to get their eye injected with Regeneron’s EYLEA. Industry research suggests that well over half of patients have chosen deteriorating vision over the inconvenience of getting their eyes injected every 1-2 months. That’s where tarcocimab comes in. In recent trials, even the “failed” trial, it has shown that 60-70% of patients can go five months or longer while maintaining the same significantly improved vision. While there are multiple therapies available for these patients, there are none that have the durability of tarcocimab. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Tarcocimab seeks to disrupt a $13 billion industry, but more importantly, fill an important gap in the macular edema market. In our conversations with doctors actively engaged in research & clinical trials, they are very eager to have a drug that they can dose less frequently. Shares have perked up since announcing the BEACON top line data, but given they still trade below cash levels, they give us a lot of upside as subsequent trials prove out that the drug works. Given the rest of the pivotal trials will read out in the next nine months, we won’t have to wait long until tarcocimab is able to serve the significant unmet medical need, and file for approval with the FDA next year. We also expect a very important update to MEIP’s regulatory strategy which will alleviate market concerns on its own drug’s timeliness to market. While many catalysts depend on a healthy market environment to play out, these do not. They can perform in any economic scenario. Trying to predict with accuracy when the stock will reflect the underlying developments is impossible. But we do know that if you miss the most material upside days of certain stocks, the realized returns are significantly more mediocre. To the extent we are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve.
Seeking Alpha • Aug 07

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences (NASDAQ:KOD) is scheduled to announce FQ1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$1.75 Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward.
分析記事 • May 18

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 17

Kodiak Sciences: Potential For Comeback After Trial Setback

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023. Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.
Seeking Alpha • Feb 25

Kodiak Sciences: KSI-301 Disappoints

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment Regeneron’s (REGN) Eylea in improvement in visual acuity. The study did not meet the primary endpoint. While KSI-301 appears safe and effective, it may not become a blockbuster.
Seeking Alpha • Feb 15

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of less frequent dosing. The first price target is $90 after positive data from the wet AMD Phase 3 trial this quarter or 70% upside potential in the stock (implied move from the options).
分析記事 • Jan 24

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 11

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. A full investment analysis is presented in the paragraphs below.

CEO報酬分析

Kodiak Sciences の収益と比較して、Victor Perlroth の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$231m

Dec 31 2025US$2mUS$792k

-US$230m

Sep 30 2025n/an/a

-US$217m

Jun 30 2025n/an/a

-US$200m

Mar 31 2025n/an/a

-US$191m

Dec 31 2024US$2mUS$757k

-US$176m

Sep 30 2024n/an/a

-US$192m

Jun 30 2024n/an/a

-US$198m

Mar 31 2024n/an/a

-US$233m

Dec 31 2023US$3mUS$721k

-US$260m

Sep 30 2023n/an/a

-US$271m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$309m

Dec 31 2022US$3mUS$691k

-US$334m

Sep 30 2022n/an/a

-US$357m

Jun 30 2022n/an/a

-US$347m

Mar 31 2022n/an/a

-US$312m

Dec 31 2021US$113mUS$655k

-US$267m

Sep 30 2021n/an/a

-US$220m

Jun 30 2021n/an/a

-US$189m

Mar 31 2021n/an/a

-US$159m

Dec 31 2020US$9mUS$591k

-US$133m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$18mUS$526k

-US$47m

報酬と市場: Victorの 総報酬 ($USD 2.50M ) は、 US市場 ($USD 7.08M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Victorの報酬は増加しましたが、会社は利益を上げていません。

CEO

Victor Perlroth (51 yo)

16.9yrs
在職期間
US$2,499,221
報酬

Dr. Victor Perlroth, M.D., Co-Founded Kodiak Sciences Inc. in 2009 and also serves as its Chairman and President. Dr. Perlroth serves as a Director and Chief Executive officer of Kodiak Sciences Inc. since...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Victor Perlroth
Co-Founder16.9yrsUS$2.50m4.71%
$ 120.6m
John Borgeson
Executive VP10.3yrsUS$1.62m0.34%
$ 8.7m
Wayne To
Chief Technology Officer1.8yrsデータなしデータなし
Dolly Chang
Chief Scientific Officer1.8yrsデータなしデータなし
Hong Liang
Senior Vice President of Development8.6yrsUS$321.91kデータなし
Stephen Raillard
Senior Vice President of Chemical Development & Manufacturing3.3yrsデータなしデータなし
Almas Qudrat
Chief Quality Officer6.3yrsデータなしデータなし
J. Velazquez-Martin
Chief Medical Officer3.3yrsデータなしデータなし
Laurent Ducay
Senior VP of Biologics Development & Manufacturingno dataデータなしデータなし
4.8yrs
平均在職期間
53yo
平均年齢

経験豊富な経営陣: KODの経営陣は 経験豊富 であると考えられます ( 4.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Victor Perlroth
Co-Founder16.9yrsUS$2.50m4.71%
$ 120.6m
Robert Profusek
Lead Independent Director7.9yrsUS$179.30k0.016%
$ 412.8k
Felix Baker
Independent Director10.7yrsUS$92.80k0%
$ 0
Richard Levy
Independent Director7.9yrsUS$142.80k0.0016%
$ 41.2k
Bassil Dahiyat
Independent Director7.9yrsUS$147.80k0%
$ 0
Charles Bancroft
Independent Director6.1yrsUS$170.30k0.042%
$ 1.1m
David Boyer
Scientific Advisorno dataデータなしデータなし
Michael IP
Scientific Advisorno dataデータなしデータなし
Sunil Patel
Scientific Advisorno dataデータなしデータなし
David Brown
Scientific Advisorno dataデータなしデータなし
Carl Regillo
Scientific Advisorno dataデータなしデータなし
Pravin Dugel
Scientific Advisorno dataデータなしデータなし
7.9yrs
平均在職期間
61yo
平均年齢

経験豊富なボード: KODの 取締役会 は 経験豊富 であると考えられます ( 7.9年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/11 03:13
終値2026/05/11 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Kodiak Sciences Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Anita DushyanthBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Ying HuangBofA Global Research